- Home
- Publications
- Publication Search
- Publication Details
Title
Dihydroergotamine (DHE) – Then and Now: A Narrative Review
Authors
Keywords
-
Journal
HEADACHE
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-11-18
DOI
10.1111/head.13700
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD® ) Device, in Healthy Adult Subjects
- (2019) Stephen B. Shrewsbury et al. HEADACHE
- The discovery and development of inhaled therapeutics for migraine
- (2019) Nicolas Vandenbussche et al. Expert Opinion on Drug Discovery
- Development and in vitro/in vivo evaluation of dihydroergotamine mesylate loaded maltodextrin-pullulan sublingual films
- (2019) Ozgur Esim et al. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
- Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine
- (2019) Peter J Goadsby et al. BRAIN
- Getting to the Heart of the Matter: Migraine, Triptans, DHE, Ditans, CGRP Antibodies, First/Second‐Generation Gepants, and Cardiovascular Risk
- (2019) Paul G. Mathew et al. HEADACHE
- Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial
- (2019) Robert Croop et al. LANCET
- Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine
- (2019) Richard B. Lipton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Discontinuation of Acute Prescription Medication for Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
- (2019) Richard B. Lipton et al. HEADACHE
- Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States
- (2018) Machaon Bonafede et al. HEADACHE
- The Prevalence and Impact of Migraine and Severe Headache in the United States: Figures and Trends From Government Health Studies
- (2018) Rebecca Burch et al. HEADACHE
- Lasmiditan is an effective acute treatment for migraine
- (2018) Bernice Kuca et al. NEUROLOGY
- Dihydroergotamine mesylate-loaded dissolving microneedle patch made of polyvinylpyrrolidone for management of acute migraine therapy
- (2017) Cetin Tas et al. JOURNAL OF CONTROLLED RELEASE
- Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
- (2017) Theo Vos et al. LANCET
- Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
- (2017) Valery L Feigin et al. LANCET NEUROLOGY
- Sustained pain relief with dihydroergotamine in migraine is potentially due to persistent binding to 5-HT1B and 5-HT1D receptors
- (2017) S Kori et al. JOURNAL OF HEADACHE AND PAIN
- Efficacy of MAP0004 in treating severe migraine
- (2017) S Kori et al. JOURNAL OF HEADACHE AND PAIN
- A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine
- (2016) Tiffini Voss et al. CEPHALALGIA
- Predicting Inadequate Response to Acute Migraine Medication: Results From the American Migraine Prevalence and Prevention (AMPP) Study
- (2016) Richard B. Lipton et al. HEADACHE
- Is the Generally Held View That Intravenous Dihydroergotamine Is Effective in Migraine Based on Wrong “General Consensus” of One Trial? A Critical Review of the Trial and Subsequent Quotations
- (2016) Goran Bekan et al. HEADACHE
- A retrospective analysis of triptan and dhe use for basilar and hemiplegic migraine
- (2016) Paul G. Mathew et al. HEADACHE
- Aprepitant for the management of nausea with inpatient IV dihydroergotamine
- (2016) Denise E. Chou et al. NEUROLOGY
- Management of Primary Headache in the Emergency Department and Inpatient Headache Unit
- (2016) Marielle Kabbouche et al. Seminars in Pediatric Neurology
- The Acute Treatment of Migraine in Adults: The American Headache Society Evidence Assessment of Migraine Pharmacotherapies
- (2015) Michael J. Marmura et al. HEADACHE
- A Comparison of the Deposition Patterns of Different Nasal Spray Formulations Using a Nasal Cast
- (2014) Yu Pu et al. AEROSOL SCIENCE AND TECHNOLOGY
- Treatment Persistence and Switching in Triptan Users: A Systematic Literature Review
- (2014) Andrew J. Messali et al. HEADACHE
- Relatively slow and long-lasting antimigraine effect of dihydroergotamine is most likely due to basic pharmacological attributes of the drug: A review
- (2013) Peer C Tfelt-Hansen CEPHALALGIA
- The International Classification of Headache Disorders, 3rd edition (beta version)
- (2013) CEPHALALGIA
- Triptan nonresponders: Do they exist and who are they?
- (2013) Michele Viana et al. CEPHALALGIA
- Dihydroergotamine: A Review of Formulation Approaches For the Acute Treatment of Migraine
- (2013) Stephen D. Silberstein et al. CNS DRUGS
- Insights into direct nose to brain delivery: current status and future perspective
- (2013) Deepti Mittal et al. DRUG DELIVERY
- Clinical Implications for Breath-Powered Powder Sumatriptan Intranasal Treatment
- (2013) Stewart J. Tepper HEADACHE
- Examination of Unmet Treatment Needs Among Persons With Episodic Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study
- (2013) Richard B. Lipton et al. HEADACHE
- Why Triptan Treatment Can Fail: Focus on Gastrointestinal Manifestations of Migraine
- (2013) Lawrence C. Newman HEADACHE
- Identifying the Factors Underlying Discontinuation of Triptans
- (2013) Rebecca E. Wells et al. HEADACHE
- Analysis of subjects with menstrually related migraine vs. Non-menstrually related migraine treated with MAP0004
- (2013) S Aurora et al. JOURNAL OF HEADACHE AND PAIN
- Effects of a Supratherapeutic Dose of Investigational Orally Inhaled Dihydroergotamine (MAP0004) on QT Interval: A Randomized, Double-Blind, Active- and Placebo-Controlled Crossover Study in Healthy Volunteers
- (2012) Shashidhar Kori et al. CLINICAL THERAPEUTICS
- Frequency and Burden of Headache-Related Nausea: Results From the American Migraine Prevalence and Prevention (AMPP) Study
- (2012) Richard B. Lipton et al. HEADACHE
- Dihydroergotamine, Ergotamine, Methysergide and Sumatriptan - Basic Science in Relation to Migraine Treatment
- (2012) Carl Dahlöf et al. HEADACHE
- Assessment of the Consistency of Absorption of Dihydroergotamine Following Oral Inhalation: Pooled Results from Four Clinical Studies
- (2012) Donald J. Kellerman et al. Journal of Aerosol Medicine and Pulmonary Drug Delivery
- Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS)
- (2012) L. M. Bloudek et al. JOURNAL OF HEADACHE AND PAIN
- Intranasal delivery of biologics to the central nervous system
- (2011) Jeffrey J. Lochhead et al. ADVANCED DRUG DELIVERY REVIEWS
- Lack of drug interaction between the migraine drug MAP0004 (orally inhaled dihydroergotamine) and a CYP3A4 inhibitor in humans
- (2011) D Kellerman et al. CEPHALALGIA
- Factors Associated With Triptan Use in Episodic Migraine: Results From the American Migraine Prevalence and Prevention Study
- (2011) Min Kyung Chu et al. HEADACHE
- Efficacy and Safety of MAP0004, Orally Inhaled DHE in Treating Migraines With and Without Allodynia
- (2011) Stewart J. Tepper et al. HEADACHE
- MAP0004, Orally Inhaled DHE: A Randomized, Controlled Study in the Acute Treatment of Migraine
- (2011) Sheena K. Aurora et al. HEADACHE
- MAP0004, Orally Inhaled Dihydroergotamine for Acute Treatment of Migraine: Efficacy of Early and Late Treatments
- (2011) Stewart J. Tepper et al. MAYO CLINIC PROCEEDINGS
- Intravenous dihydroergotamine for inpatient management of refractory primary headaches
- (2011) A. J. Nagy et al. NEUROLOGY
- Reduced Adverse Event Profile of Orally Inhaled DHE (MAP0004) vs IV DHE: Potential Mechanism
- (2009) Robert O. Cook et al. HEADACHE
- A Randomized, Double Blind, Placebo-Controlled Study of MAP0004 in Adult Patients With Migraine
- (2009) Sheena K. Aurora et al. HEADACHE
- Intrapulmonary and intravenous administrations of dihydroergotamine mesylate have similar cardiovascular effects in the conscious dog
- (2008) S B Shrewsbury et al. BRITISH JOURNAL OF PHARMACOLOGY
- History of the Use of Ergotamine and Dihydroergotamine in Migraine From 1906 and Onward
- (2008) PC Tfelt-Hansen et al. CEPHALALGIA
- Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics
- (2008) Stephen B. Shrewsbury et al. CURRENT MEDICAL RESEARCH AND OPINION
- The Burden of Migraine in the United States: Current and Emerging Perspectives on Disease Management and Economic Analysis
- (2008) Elisabeth Hazard et al. VALUE IN HEALTH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started